| 2003 | | 15d-PGJ2 and rosiglitazone suppress Janus kinase-STAT inflammatory signaling through induction of suppressor of cytokine signaling 1 (SOCS1) and SOCS3 in glia. | 박은정, 조은혜, 주일로 |
| 2022 | | A Real-World Study of Long-Term Safety and Efficacy of Lobeglitazone in Korean Patients with Type 2 Diabetes Mellitus | 한승진 |
| 2017 | | Anti-fibrogenic effect of PPAR-gamma agonists in human intestinal myofibroblasts | 신성재, 이광재, 이기명 |
| 2017 | | Cardiovascular events associated with second-line anti-diabetes treatments: analysis of real-world Korean data | 김대중, 하경화 |
| 2020 | | Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer | 박복남, 변혜은, 안영실, 윤준기, 이수진 |
| 2007 | | Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model. | 김대중, 김혜진, 이관우 |
| 2002 | | Effects of peroxisome proliferator-activated receptor agonists on LPS-induced neuronal death in mixed cortical neurons: associated with iNOS and COX-2. | 문창현, 백은주, 이수환 |
| 2007 | | Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. | 김대중, 이관우 |
| 2011 | | Fat redistribution preferentially reflects the anti-inflammatory benefits of pioglitazone treatment. | 김혜진 |
| 2017 | | Impact of clinical evidence communications and drug regulation changes concerning rosiglitazone on prescribing patterns of antidiabetic therapies | 김대중, 이광재 |
| 2015 | | Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. | 이관우 |
| 2006 | | Mitochondria are impaired in the adipocytes of type 2 diabetic mice. | 윤계순 |
| 2006 | | Peroxisome proliferator-activated receptors-gamma activator, ciglitazone, inhibits human melanocyte growth through induction of apoptosis. | 강희영 |
| 2007 | | PPAR-gamma agonist, ciglitazone, increases pigmentation and migration of human melanocytes. | 강희영 |
| 2005 | | Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. | 김대중 |
| 2019 | | Second-line glucose-lowering drugs added to metformin and the risk of hospitalization for heart failure: A nationwide cohort study | 김대중, 하경화 |
| 2006 | | The 11482G >A polymorphism in the perilipin gene is associated with weight gain with rosiglitazone treatment in type 2 diabetes. | 김혜진 |
| 2007 | | The different mechanisms of insulin sensitizers to prevent type 2 diabetes in OLETF rats. | 김대중 |
| 2007 | | The increase in abdominal subcutaneous fat depot is an independent factor to determine the glycemic control after rosiglitazone treatment. | 김혜진 |
| 2006 | | The long-term effects of rosiglitazone on serum lipid concentrations and body weight. | 김혜진 |
| 2016 | | Troglitazone Stimulates Cancer Cell Uptake of 18F-FDG by Suppressing Mitochondrial Respiration and Augments Sensitivity to Glucose Restriction | 이수진 |
